Doxycycline in the Coronavirus Disease 2019 Therapy

Posted on | Posted on John Murphy | Leave a Comment on Doxycycline in the Coronavirus Disease 2019 Therapy

Karolina Dorobisz, 1 Tadeusz Dorobisz, 2 Dariusz Janczak, 2 and Tomasz Zatoński 1 Author information Article notes Copyright and License information PMC Disclaimer Ther Clin Risk Manag. 2021; 17: 1023–1026. Published online 2021 Sep 21. doi: 10.2147/TCRM.S314923 PMCID: PMC8464303PMID: 34584416 Abstract Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce […]

Potential New Treatment for “Brain Fog” in Long COVID Patients

Posted on | Posted on John Murphy | Leave a Comment on Potential New Treatment for “Brain Fog” in Long COVID Patients

December 12, 2022 by Isabella Backman Individuals with long COVID, sometimes referred to as “long-haulers,” experience symptoms that may persist for weeks, months, or even years after their acute viral infection. While symptoms vary widely, a common complaint among patients is “brain fog”—a colloquial term for significant, persistent cognitive deficits, with consistent impairment of executive […]

Ritalin (Methylphenidate) For Chronic Fatigue Syndrome and Fibromyalgia

Posted on | Posted on John Murphy | Leave a Comment on Ritalin (Methylphenidate) For Chronic Fatigue Syndrome and Fibromyalgia

Methylphenidate (Ritalin, Concerta) Ritalin Is… a central nervous system stimulant. Created in 1954, Ritalin has been in use for over sixty years. (Check out a History of Ritalin here). It was first FDA approved in 1955 to treat ‘hyperactivity’ and later was approved to treat attention deficit hyperactivity disorder (ADHD). Ritalin increases extracellular levels of dopamine […]

New research helps explain how Ritalin sharpens attention

Posted on | Posted on John Murphy | Leave a Comment on New research helps explain how Ritalin sharpens attention

Date: April 29, 2022 Source: University of Pittsburgh Science Daily Summary: Researchers found animals that had taken methylphenidate performed better on a visual task of attention, and that the improvement happened exactly when that same metric of neuron activity shifted. Even half a century after a drug comes on the market, scientists can still learn […]

Exercise is the Most Important Medicine for COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Exercise is the Most Important Medicine for COVID-19

Torres, Georgia PhD; Constantinou, Demitri MBChB, FACSM; Gradidge, Philippe PhD; Patel, Deepak MD; Patricios, Jon MBBCh, MMedSci Current Sports Medicine Reports 22(8):p 284-289, August 2023. | DOI: 10.1249/JSR.0000000000001092 Abstract COVID-19 infection and long COVID affect multiple organ systems, including the respiratory, cardiovascular, renal, digestive, neuroendocrine, musculoskeletal systems, and sensory organs. Exerkines, released during exercise, have a potent crosstalk effect […]

Risk of smell loss from covid has plummeted since 2020

Posted on | Posted on John Murphy | Leave a Comment on Risk of smell loss from covid has plummeted since 2020

New research shows steep drops in the rates of smell loss with recent omicron variants By Aara’L Yarber August 2023 When the pandemic began, losing your sense of smell was considered a key indicator of covid-19, and the condition affected about half of those who tested positive for the coronavirus. However, a new study reveals that the chance of smell loss […]

Can This Common Medication Help Reduce The Risk Of Long COVID?

Posted on | Posted on John Murphy | Leave a Comment on Can This Common Medication Help Reduce The Risk Of Long COVID?

A recent study suggests that the treatment may help some high-risk people following an infection. By Casey Clark Aug 29, 2023 It seems like every time you turn on the news or open your phone, new information about COVID-19 pops up. Most of this information is pertinent to the latest variant EG.5, also called “Eris,” but recently, other more […]

SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy

Posted on | Posted on John Murphy | Leave a Comment on SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy

Marcelo Merello, Kailash P Bhatia, Jose A Obeso Published: November 27, 2020 DOI: https://doi.org/10.1016/S1474-4422(20)30442-7 Lancet Neurology VOLUME 20, ISSUE 2, P94-95, FEBRUARY 2021 During the pandemic it has become clear that severe acure respiratory syndrome coronavirus (SARS-CoV-2) causes not just respiratory disease, but can affect multiple organs and tissues. Of note is the involvement of the CNS […]

Clinical characteristics and outcome of COVID-19 patients with Parkinson’s disease: a hospital-based case–control study in Shanghai, China

Posted on | Posted on John Murphy | Leave a Comment on Clinical characteristics and outcome of COVID-19 patients with Parkinson’s disease: a hospital-based case–control study in Shanghai, China

Front. Aging Neurosci., 05 May 2023 Sec. Parkinson’s Disease and Aging-related Movement DisordersVolume 15 – 2023 | https://doi.org/10.3389/fnagi.2023.1138418 Li Wu1† Jun Shen1† Yuhan Jiang1 Xiaolei Shen1 Ping Wang1 Xin Nie2 Wenyan Kang3,4* Jianren Liu1* Wei Chen1* Background: Clinical manifestations of Parkinson’s disease (PD) after Corona Virus Disease 2019 (COVID-19) infection are poorly investigated. Objective: We aimed to explore the clinical features and outcomes of hospitalized PD […]

Early-stage trial for Parkinson’s disease therapy shows signs of promise

Posted on | Posted on John Murphy | Leave a Comment on Early-stage trial for Parkinson’s disease therapy shows signs of promise

Small trial of Bemdaneprocel, which aims to replace dopamine-producing neurons, raises hope for treatment. Hannah Devlin Science correspondent 28 Aug 2023 03.00 EDT Scientists have reported early success in a trial of an experimental cell therapy for Parkinson’s disease, raising hope for patients. Bemdaneprocel therapy is at an early stage, and the year-long trial involved just […]